Ekkehard Grünig1, Alison MacKenzie2, Andrew J Peacock2, Christina A Eichstaedt1,3, Nicola Benjamin1, Robert Nechwatal4, Silvia Ulrich5, Stéphanie Saxer5, Maurizio Bussotti6, Marinella Sommaruga6, Stefano Ghio7, Lina Gumbiene8,9, Eglė Palevičiūtė8,9, Elena Jurevičienė8,9, Antonio Cittadini10, Anna A Stanziola11, Alberto M Marra1,12, Gabor Kovacs13,14, Horst Olschewski13,14, Joan-Albert Barberà15, Isabel Blanco15, Martijn A Spruit16,17,18,19, Frits M E Franssen20, Anton Vonk Noordegraaf21, Abílio Reis22, Mário Santos22, Sofia Gonçalves Viamonte23, Heleen Demeyer24,25,26, Marion Delcroix24, Eduardo Bossone27, Martin Johnson2. 1. Centre for Pulmonary Hypertension, Thoraxklinik Heidelberg gGmbH at Heidelberg University Hospital, Translational Lung Research Center Heidelberg (TLRC), German Center for Lung Research (DZL), Röntgenstraße 1, D-69126 Heidelberg, Germany. 2. Scottish Pulmonary Vascular Unit, Golden Jubilee National Hospital, Glasgow, UK. 3. Laboratory for Molecular Diagnostics, Institute of Human Genetics, Heidelberg University, Heidelberg, Germany. 4. Rehabilitation Center Koenigstuhl, Heidelberg, Germany. 5. Clinic of Pulmonology, University Hospital and University of Zurich, Zurich, Switzerland. 6. Cardiac Rehabilitation Department, IRCCS Maugeri Clinical Scientific Institutes, Milan, Italy. 7. Divisione di Cardiologia, Fondazione IRCCS Policlinico S Matteo, Pavia, Italy. 8. Competence Centre of Pulmonary Hypertension, Vilnius University Hospital Santaros Klinikos, Vilnius, Lithuania. 9. Faculty of Medicine, Institute of Clinical Medicine, Vilnius University, Vilnius, Lithuania. 10. Department of Translational Medical Sciences, "Federico II" University, Naples, Italy. 11. Department of Clinical Medicine and Surgery, "Federico II" University, Naples, Italy. 12. Department of Cardiovascular Imaging, IRCCS S.D.N., Naples, Italy. 13. Division of Pulmonology, Department of Internal Medicine, Medical University of Graz, Graz, Austria. 14. Ludwig Boltzmann Institute for Lung Vascular Research, Graz, Austria. 15. Department of Pulmonary Medicine, Hospital Clinic-IDIBAPS, University of Barcelona, Barcelona and Biomedical Research Networking Center on Respiratory Diseases (CIBERES), Spain. 16. Research and Development, Ciro, Horn, Netherlands. 17. Department of Respiratory Medicine, Maastricht University Medical Centre (MUMC+), Maastricht, The Netherlands. 18. NUTRIM School of Nutrition and Translational Research in Metabolism, Maastricht, The Netherlands. 19. REVAL-Rehabilitation Research Center, BIOMED-Biomedical Research Institute, Faculty of Rehabilitation Sciences, Hasselt University, Diepenbeek, Belgium. 20. Department of Research and Education, CIRO, Horn, The Netherlands. 21. Department of Pulmonology, Amsterdam Cardiovascular Sciences, Amsterdam UMC, VU University Medical Center, Amsterdam, The Netherlands. 22. Department of Internal Medicine, Hospital Geral de Santo António, Porto, Portugal. 23. Centro de Rehabilitação do Norte/Centro Hospitalar Vila Nova de Gaia Espinho, Porto, Portugal. 24. Department of Pneumology, University Hospital Leuven, Leuven, Belgium. 25. Department of Rehabilitation Sciences, KU Leuven - University of Leuven, Leuven, Belgium. 26. Department of Rehabilitation Sciences, Ghent University, Ghent, Belgium. 27. Department of Cardiology, Antonio Carderelli Hospital, Naples, Italy.
Abstract
AIMS: This prospective, randomized, controlled, multicentre study aimed to evaluate efficacy and safety of exercise training in patients with pulmonary arterial (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH). METHODS AND RESULTS: For the first time a specialized PAH/CTEPH rehabilitation programme was implemented in 11 centres across 10 European countries. Out of 129 enrolled patients, 116 patients (58 vs. 58 randomized into a training or usual care control group) on disease-targeted medication completed the study [85 female; mean age 53.6 ± 12.5 years; mean pulmonary arterial pressure 46.6 ± 15.1 mmHg; World Health Organization (WHO) functional class II 53%, III 46%; PAH n = 98; CTEPH n = 18]. Patients of the training group performed a standardized in-hospital rehabilitation with mean duration of 25 days [95% confidence interval (CI) 17-33 days], which was continued at home. The primary endpoint, change of 6-min walking distance, significantly improved by 34.1 ± 8.3 m in the training compared with the control group (95% CI, 18-51 m; P < 0.0001). Exercise training was feasible, safe, and well-tolerated. Secondary endpoints showed improvements in quality of life (short-form health survey 36 mental health 7.3 ± 2.5, P = 0.004), WHO-functional class (training vs. control: improvement 9:1, worsening 4:3; χ2P = 0.027) and peak oxygen consumption (0.9 ± 0.5 mL/min/kg, P = 0.048) compared with the control group. CONCLUSION: This is the first multicentre and so far the largest randomized, controlled study on feasibility, safety, and efficacy of exercise training as add-on to medical therapy in PAH and CTEPH. Within this study, a standardized specialized training programme with in-hospital start was successfully established in 10 European countries. Published on behalf of the European Society of Cardiology. All rights reserved.
AIMS: This prospective, randomized, controlled, multicentre study aimed to evaluate efficacy and safety of exercise training in patients with pulmonary arterial (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH). METHODS AND RESULTS: For the first time a specialized PAH/CTEPH rehabilitation programme was implemented in 11 centres across 10 European countries. Out of 129 enrolled patients, 116 patients (58 vs. 58 randomized into a training or usual care control group) on disease-targeted medication completed the study [85 female; mean age 53.6 ± 12.5 years; mean pulmonary arterial pressure 46.6 ± 15.1 mmHg; World Health Organization (WHO) functional class II 53%, III 46%; PAH n = 98; CTEPH n = 18]. Patients of the training group performed a standardized in-hospital rehabilitation with mean duration of 25 days [95% confidence interval (CI) 17-33 days], which was continued at home. The primary endpoint, change of 6-min walking distance, significantly improved by 34.1 ± 8.3 m in the training compared with the control group (95% CI, 18-51 m; P < 0.0001). Exercise training was feasible, safe, and well-tolerated. Secondary endpoints showed improvements in quality of life (short-form health survey 36 mental health 7.3 ± 2.5, P = 0.004), WHO-functional class (training vs. control: improvement 9:1, worsening 4:3; χ2P = 0.027) and peak oxygen consumption (0.9 ± 0.5 mL/min/kg, P = 0.048) compared with the control group. CONCLUSION: This is the first multicentre and so far the largest randomized, controlled study on feasibility, safety, and efficacy of exercise training as add-on to medical therapy in PAH and CTEPH. Within this study, a standardized specialized training programme with in-hospital start was successfully established in 10 European countries. Published on behalf of the European Society of Cardiology. All rights reserved.
Authors: Henrik Pettersson; Helene Alexanderson; Janet L Poole; Janos Varga; Malin Regardt; Anne-Marie Russell; Yasser Salam; Kelly Jensen; Jennifer Mansour; Tracy Frech; Carol Feghali-Bostwick; Cecília Varjú; Nancy Baldwin; Matty Heenan; Kim Fligelstone; Monica Holmner; Matthew R Lammi; Mary Beth Scholand; Lee Shapiro; Elizabeth R Volkmann; Lesley Ann Saketkoo Journal: Best Pract Res Clin Rheumatol Date: 2021-07-01 Impact factor: 4.991
Authors: Mark A Faghy; Ross Arena; Abraham Samuel Babu; Jeffrey W Christle; Susan Marzolini; Dejana Popovic; Amber Vermeesch; Nicolaas P Pronk; Lee Stoner; Andy Smith Journal: Prog Cardiovasc Dis Date: 2022-07-13 Impact factor: 11.278
Authors: Paula Appenzeller; Fiorenza Gautschi; Julian Müller; Mona Lichtblau; Stéphanie Saxer; Simon R Schneider; Esther I Schwarz; Silvia Ulrich Journal: ERJ Open Res Date: 2022-06-20
Authors: Maria Wieteska-Miłek; Sebastian Szmit; Michał Florczyk; Anna Witowicz; Marcin Kurzyna Journal: Int J Environ Res Public Health Date: 2022-07-08 Impact factor: 4.614
Authors: Bernhard Rauch; Annett Salzwedel; Birna Bjarnason-Wehrens; Christian Albus; Karin Meng; Jean-Paul Schmid; Werner Benzer; Matthes Hackbusch; Katrin Jensen; Bernhard Schwaab; Johann Altenberger; Nicola Benjamin; Kurt Bestehorn; Christa Bongarth; Gesine Dörr; Sarah Eichler; Hans-Peter Einwang; Johannes Falk; Johannes Glatz; Stephan Gielen; Maurizio Grilli; Ekkehard Grünig; Manju Guha; Matthias Hermann; Eike Hoberg; Stefan Höfer; Harald Kaemmerer; Karl-Heinz Ladwig; Wolfgang Mayer-Berger; Maria-Inti Metzendorf; Roland Nebel; Rhoia Clara Neidenbach; Josef Niebauer; Uwe Nixdorff; Renate Oberhoffer; Rona Reibis; Nils Reiss; Daniel Saure; Axel Schlitt; Heinz Völler; Roland von Känel; Susanne Weinbrenner; Ronja Westphal Journal: J Clin Med Date: 2021-05-19 Impact factor: 4.241
Authors: Olga Vriz; Paolo Palatini; Lawrence Rudski; Paolo Frumento; Jarosław D Kasprzak; Francesco Ferrara; Rosangela Cocchia; Luna Gargani; Karina Wierzbowska-Drabik; Valentina Capone; Brigida Ranieri; Andrea Salzano; Anna Agnese Stanziola; Alberto Maria Marra; Roberto Annunziata; Salvatore Chianese; Salvatore Rega; Teresa Saltalamacchia; Renato Maramaldi; Chiara Sepe; Giuseppe Limongelli; Filippo Cademartiri; Antonello D'Andrea; Michele D'Alto; Raffaele Izzo; Nicola Ferrara; Ciro Mauro; Antonio Cittadini; Grünig Ekkehard; Marco Guazzi; Eduardo Bossone Journal: J Clin Med Date: 2022-01-17 Impact factor: 4.241